Key result
Ginsenoside Rb1 improves cardiac function and reduces weight in diabetic mice via the adipocytokine pathway.
Why the study?
The role of ginsenoside Rb1 in treating diabetic cardiomyopathy remains unclear.
Does ginsenoside Rb1 improve cardiac function and metabolic parameters in diabetic mice?
Does ginsenoside Rb1 improve cardiac function and metabolic parameters in diabetic mice?
Ginsenoside Rb1 protects against diabetic cardiomyopathy in mice by regulating the adipocytokine pathway, reducing lipid accumulation and oxidative stress.
Answers are grounded in this paper and cite their sources.
Ginsenoside Rb1 may improve cardiac parameters in diabetic mice; leaves open whether adipocytokine effects translate to human diabetic cardiomyopathy.
PURPOSE: Obesity and diabetes are often accompanied by chronic inflammation and insulin resistance, which lead to complications such as diabetic cardiomyopathy. Ginsenoside Rb1 has been used to treat diabetes and obesity and reduce inflammation as well as risk of heart diseases. However, the role of ginsenoside Rb1 in treating diabetic cardiomyopathy remains unclear. METHODS: Diabetic mice were administered ginsenoside Rb1 for 12 weeks, and their body weight, body fat, and blood glucose levels as well as and serum insulin, lipids, and adipocytokine levels were assessed. Lipid accumulation, pathological morphology of the adipose tissue, liver, and heart were examined. Western blot and qRT-PCR were performed to investigate the molecular changes in response to ginsenoside Rb1 treatment. RESULTS: Ginsenoside Rb1 treatment significantly reduced body weight and body fat, attenuated hyperglycemia and hyperlipidemia, and ameliorated insulin resistance and abnormal levels of adipocytokines in diabetic mice. In addition, lipid accumulation and inflammation reduced while the functions of heart improved in the ginsenoside Rb1-treated group. Furthermore, antioxidant function improved in the ginsenoside Rb1-treated diabetic hearts. PCR and Western blotting analyses revealed that the lipid-lowering effect of ginsenoside Rb1 and the resulting improvement of cardiac function could be attributed to the adipocytokine pathway, which promoted energy homeostasis and alleviated cardiac dysfunction. CONCLUSION: Ginsenoside Rb1 lowered lipid levels in a adipocytokine-mediated manner and attenuated hyperglycemia/hyperlipidemia-induced oxidative stress, hypertrophy, inflammation, fibrosis, and apoptosis in cardiomyocytes.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied Diabetic cardiomyopathy. Ginsenoside Rb1 was evaluated. Ginsenoside Rb1 treatment for 12 weeks significantly reduced body weight, attenuated hyperglycemia and hyperlipidemia, and improved cardiac function in diabetic mice via the adipocytokine pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: